General Information of Drug Combination (ID: DCLRTBY)

Drug Combination Name
Picoplatin Hepzato
Indication
Disease Entry Status REF
Anaplastic large cell lymphoma Investigative [1]
Component Drugs Picoplatin   DM0PIY6 Hepzato   DM2AZPP
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: SR
Zero Interaction Potency (ZIP) Score: 4.05
Bliss Independence Score: 6.6
Loewe Additivity Score: 4.04
LHighest Single Agent (HSA) Score: 6.37

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Lung adenocarcinoma DCNJ472 HOP-62 Investigative [4]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976